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orthodox clinicians to justify referral to homoeopathic
services. The use of randomised controlled trials to test
the legitimacy of homoeopathic treatments is the latest
chapter in an ideological and scientific struggle
between homoeopathy and orthodox medicine going
back to the 19th century.5 The fervour of this struggle
is reflected in the 58 electronic responses to another
trial of homoeopathy reported in the BMJ.6
Are the results of placebo controlled trials in
homoeopathy convincing? Linde et al’s meta›analysis
of 89 trials suggests an effect of homoeopathic
medicines greater than placebo.7 The aggregated effect
size of homoeopathic treatments, when possible publi›
cation bias is taken into account or only high quality
trials are included, is modest.8 How seriously clinicians
take these findings depends on their prior beliefs.9 If
you cannot conceive of highly diluted solutions with
undetectable drug concentrations having a biological
effect, then no matter how well designed the trial or
robust the meta›analysis, a positive result will not
change your view. If you are less concerned about the
integrity of our model of the universe or are intrigued
by controversial laboratory work showing the activity
of highly diluted histamine solutions10 than the overall
positive result of the trials makes it easier to take
homoeopathy seriously.
Despite homoeopathy’s popularity with patients,
orthodox medicine has had the upper hand in terms of
institutional support, research funding, and strong
evidence of effectiveness. Nevertheless, the flurry of trials
in the past 20 years has changed the terms of the debate.
At the very least, those who consider homoeopathy to be
absurd have had to muster different philosophical and
methodological arguments to defend their position.
Randomised controlled trials may be efficient arbiters of
clinical effectiveness, but they are not particularly good
for resolving philosophical disputes.
Current trials are of a high methodological standard
and, if positive, may sway agnostics. Opponents of
homoeopathy have made it clear that no number of well
designed trials showing an effect greater than placebo
will overcome their prior belief that homoeopathy
cannot work. Research funding is a scarce resource.
Unlike other commentators in this journal,11 we believe
that new trials of homoeopathic medicines against
placebo are no longer a research priority. The question
whether ultramolecular dilutions can have any measur›
able physical effect, a scientific rather than philosophical
question, is best tackled with laboratory methods.
However, there is still a role for pragmatic trials compar›
ing the effect and cost effectiveness of orthodox and
homoeopathic treatments. Within the homoeopathic
medical community and other groups that use
homoeopathy, such as anthroposophical physicians,12
there is a call for outcome studies to evaluate the
individualised treatment decisions that are at the heart
of their clinical method and compare outcomes to
orthodox treatment.13
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Brain drain and health professionals
A global problem needs global solutions
Migration of medical professionals from devel›oping countries has become a majorconcern. This brain drain worsens the
already depleted healthcare resources in poor coun›
tries and widens the gap in health inequities
worldwide. It is time that international organisations
collaborated to protect the value of this “intellectual
property”: where medical professionals cannot be dis›
suaded from moving, the country that trained them
should at least gain from their movement.
In Africa alone, where health needs and problems
are greatest, around 23 000 qualified academic profes›
sionals emigrate annually.1 Information from South
African medical schools suggests that a third to a half
of its graduates emigrate to the developed world.2 The
loss of nurses has been even more extreme—for exam›
ple, more than 150 000 Filipino nurses3 and 18 000
Zimbabwean nurses4 work abroad. A recent report
from the United Kingdom estimated that 31% of its
doctors and 13% of its nurses are born overseas; in
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London the figures are 23% and 47% respectively.5
These reported figures are likely to be underestimates
as many migrate unofficially.
The cost implications are significant. With 600 of its
medical graduates registered in New Zealand, the
financial cost to South Africa was estimated at $37m.6
The United Nations Commission for Trade and Devel›
opment has estimated that each migrating African
professional represents a loss of $184 000 to Africa.7
Paradoxically, Africa spends $4bn a year on the salaries
of 100 000 foreign experts.1 8 In an example of brain
drain within the country, Kenya estimates that only 600
doctors work in public hospitals out of more than 5000
registered9; the rest have moved abroad or are working
in the private sector. “Brain waste” also occurs when
health workers end up working outside the health sec›
tor or as unskilled labour in the country they move to.
Some benefits may also result for the exporting
country. These include substantial financial remit›
tances from expatriates, improved training, and long
term professional networks. The adverse effects,
however, are likely to predominate.
What factors influence medical professionals to
emigrate? Key reasons include poor remuneration, bad
working conditions, an oppressive political climate,
persecution of intellectuals, and discrimination.
Researchers cite lack of funding, poor facilities, limited
career structures, and poor intellectual stimulation as
important reasons for dissatisfaction. Other key
reasons for emigrating are personal ones. These
include security, the threat of violence,10 and the wish to
provide a good education for their children.
Some countries which have shown the foresight
and commitment to improve domestic conditions have
succeeded in effecting a brain gain by attracting back
medical professionals. Thailand and Ireland have
reverse brain drain programmes offering generous
research funding and monetary incentives as well as
services and assistance. Developing countries need to
address the structural, political, and economic prob›
lems that lead to the brain drain.
Possible solutions include demanding compensation
from departing professionals; delaying their departure
through compulsory service; increasing salaries in the
public health sector; permitting health professionals in
the public sector to do some private practice; providing
educational benefits for their children; and training
paramedics who can fulfil many of the roles of doctors
but whose qualifications are not recognised outside the
country. They must aim to provide a stimulating
environment for professional growth with adequate
funding, facilities, and a vibrant intellectual community.
Funding agencies should put more resources into
improving the conditions and training for health care
professionals and researchers in low income countries.
Importantly, when such training is provided abroad it
should be relevant and applicable to the problems of
the country of origin so that the difficulties and frustra›
tions experienced by those returning to a poorer envi›
ronment are minimised.
On their part, developed countries should think of
the impact of brain drain on health care in poorer
countries and consider reimbursing these countries for
the cost of training the health professionals they
import. They need bilateral agreements with these
countries and a recruiting process that would minimise
the adverse effects on the health care of the exporting
countries. The recently published guidelines by the UK
Department of Health11 address the ethical issues
involved in the international recruitment of nurses and
doctors. They recognise that old practices of recruit›
ment without regard to the negative impacts in the
country of origin are no longer acceptable. Clearly, we
need better evidence on the extent of the problem of
brain drain, its impact on both countries, and the effec›
tiveness of measures to deal with it.
What part should international organisations play,
given the global nature of the brain drain? Just as intel›
lectual property rights need to be discussed by
developed and developing countries together, so also
should the preservation of the intellectual property of a
nation, embodied in its health professionals, be
addressed by international organisations. The World
Health Organization could convene a forum of govern›
ments and international organisations such as the
International Organization for Migration, the United
Nations Educational, Scientific, and Cultural Organiza›
tion, the United Nations Development Programme, the
World Bank, the World Medical Association, and the
Council of International Organizations of Medical
Societies. They could agree on a declaration and an
international code of ethical guidelines,12 keeping in
mind the harm that migration of medical professionals
may cause. Currently the office of the Pan American
Health Organization is working closely with interested
stakeholders and member countries on a programme
of managed migration of nurses in the Caribbean,
traditionally a major source for recruiters. A global per›
spective, agreed ethical principles between countries,
and a systematic approach using the convening power
of international organizations should be the way to
address the problem of brain drain.
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